Mucin as a therapeutic target in pseudomyxoma peritonei

Haroon A. Choudry; Mark E. O'Malley; Zong Sheng Guo; Herbert J. Zeh; David L. Bartlett

doi:10.1002/jso.23146

Mucin as a therapeutic target in pseudomyxoma peritonei

Haroon A. Choudry, Mark E. O'Malley, Zong Sheng Guo, Herbert J. Zeh, David L. Bartlett

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

Original language	English (US)
Pages (from-to)	911-917
Number of pages	7
Journal	Journal of Surgical Oncology
Volume	106
Issue number	7
DOIs	https://doi.org/10.1002/jso.23146
State	Published - Dec 2012
Externally published	Yes

Keywords

chemoperfusion
goblet cells
mucin
pseudomyxoma peritonei
targeted therapy
transcriptional regulation

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.23146

Cite this

@article{0aa316ceee67415eb24768f866d1875f,

title = "Mucin as a therapeutic target in pseudomyxoma peritonei",

abstract = "Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. {\textcopyright} 2012 Wiley Periodicals, Inc.",

keywords = "chemoperfusion, goblet cells, mucin, pseudomyxoma peritonei, targeted therapy, transcriptional regulation",

author = "Choudry, {Haroon A.} and O'Malley, {Mark E.} and Guo, {Zong Sheng} and Zeh, {Herbert J.} and Bartlett, {David L.}",

year = "2012",

month = dec,

doi = "10.1002/jso.23146",

language = "English (US)",

volume = "106",

pages = "911--917",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Mucin as a therapeutic target in pseudomyxoma peritonei

AU - Choudry, Haroon A.

AU - O'Malley, Mark E.

AU - Guo, Zong Sheng

AU - Zeh, Herbert J.

AU - Bartlett, David L.

PY - 2012/12

Y1 - 2012/12

N2 - Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

AB - Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy? J. Surg. Oncol. 2012; 106:911-917. © 2012 Wiley Periodicals, Inc.

KW - chemoperfusion

KW - goblet cells

KW - mucin

KW - pseudomyxoma peritonei

KW - targeted therapy

KW - transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=84868348442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868348442&partnerID=8YFLogxK

U2 - 10.1002/jso.23146

DO - 10.1002/jso.23146

M3 - Review article

C2 - 22585683

AN - SCOPUS:84868348442

SN - 0022-4790

VL - 106

SP - 911

EP - 917

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 7

ER -

Mucin as a therapeutic target in pseudomyxoma peritonei

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this